5NN3

Crystal structure of human lysosomal acid-alpha-glucosidase, GAA

5NN3 の概要

• エントリーDOI: 10.2210/pdb5nn3/pdb
• 分子名称: Lysosomal alpha-glucosidase, 1,2-ETHANEDIOL, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, ... (11 entities in total)
• 機能のキーワード: glycoside hydrolase, lysosome, glycogen catabolism, pompe disease, hydrolase
• 由来する生物種: Homo sapiens (Human)
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 101294.13

構造登録者

Roig-Zamboni, V.,Cobucci-Ponzano, B.,Iacono, R.,Ferrara, M.C.,Germany, S.,Parenti, G.,Bourne, Y.,Moracci, M. (登録日: 2017-04-08, 公開日: 2017-10-25, 最終更新日: 2024-11-20)

主引用文献

Roig-Zamboni, V.,Cobucci-Ponzano, B.,Iacono, R.,Ferrara, M.C.,Germany, S.,Bourne, Y.,Parenti, G.,Moracci, M.,Sulzenbacher, G.
Structure of human lysosomal acid alpha-glucosidase-a guide for the treatment of Pompe disease.
Nat Commun, 8:1111-1111, 2017

PubMed Abstract: Pompe disease, a rare lysosomal storage disease caused by deficiency of the lysosomal acid α-glucosidase (GAA), is characterized by glycogen accumulation, triggering severe secondary cellular damage and resulting in progressive motor handicap and premature death. Numerous disease-causing mutations in the gaa gene have been reported, but the structural effects of the pathological variants were unknown. Here we present the high-resolution crystal structures of recombinant human GAA (rhGAA), the standard care of Pompe disease. These structures portray the unbound form of rhGAA and complexes thereof with active site-directed inhibitors, providing insight into substrate recognition and the molecular framework for the rationalization of the deleterious effects of disease-causing mutations. Furthermore, we report the structure of rhGAA in complex with the allosteric pharmacological chaperone N-acetylcysteine, which reveals the stabilizing function of this chaperone at the structural level.

PubMed: 29061980
DOI: 10.1038/s41467-017-01263-3

実験手法

X-RAY DIFFRACTION (1.9 Å)